GlassScriptPhysician profile
Sidney Kent Griffith
NPI 1285628867
$11,944.56
in general payments reported to CMS, 2019-2025
49 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $735 · 2021: $2,010 · 2022: $2,820 · 2023: $2,036 · 2024: $2,223 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,068.57 | 2019-2025 | |
| Lilly USA, LLC | $829.28 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $614.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $477.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $469.97 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.38 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $436.32 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $413.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $357.94 | 2019-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $304.30 | 2019-2021 | |
| Allergan, INC. | $304.03 | 2020 | |
| Pfizer INC. | $283.29 | 2019-2025 | |
| Abbott Laboratories | $272.51 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $239.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $216.69 | 2019-2023 | Belsomra, Steglujan, Steglatro |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.